A recent report on a drop of blood-testable cancer has drawn attention. In 2015, the number of new cancer cases in China was approximately 4.3 million, and the number of deaths was 2.8 million. That is, the average number of new cancer patients per minute has exceeded 8 people.

However, it is even more saddened by the fact that early cancers have no obvious symptoms and are often discovered late. Ninety percent of early cancers can be cured.

As a result, a new global issue, how to detect cancer in a timely manner has plagued the medical community at home and abroad. For more than two decades, Luo Yongzhang and his team at the School of Life Sciences at Tsinghua University have been searching for answers and have made historic breakthroughs.

This Chinese medical team has invented a “mirror mirror” that can make the cancer emerge as early as possible and save the lives of tens of millions of people.

According to the prediction of the World Health Organization, 2020, the number of new cancer cases in the world will reach 20 million, and 12 million people will die from cancer. Finding an effective means of cancer treatment and monitoring is the direction that many scientists around the world are striving for. However, in reality, how to detect cancer in a timely manner has plagued the medical community at home and abroad.

Ninety percent of early cancers can be cured. The tumor is secretive, although the early cancer is a good cure, but because there is no obvious symptoms, it is often easy to be found in the late stage. Late stage tumors have metastasized and spread and it is difficult to treat them.

Luo Yongzhang painfully saw this fact when he graduated from college in the 1980s:

"After graduating from college, one of my classmates was found to have cancer and was pancreatic cancer. He died less than half a year after surgery. Before my classmate died, I hope that I can learn about tumor-related specialties."

The good student died of cancer and deeply stimulated Luo Yongzhang. During his studies in the United States, he resolutely changed his chemistry major from undergraduate science to biology. From then on, he started his career in the fight against cancer.

In 1998, an accidental opportunity led Luo Yongzhang to return to China and developed a new drug for cancer resistance that drastically reduced drug prices. However, the problem of early detection of tumors has plagued Luo Yongzhang.

As early as 1989, academia discovered that the heat shock protein 90α in the human body could become a tumor discovery marker. For more than two decades, the research teams of various countries around the world have published more than 10,000 papers around this protein, and three American academicians and three European academicians have been produced. However, no research results have been translated into products.

In 2009, Luo Yongzhang's team began to intervene in the research, and through the large-scale preparation of recombinant proteins, a structurally stable heat shock protein 90α was artificially prepared. This means that they are free to "make" this protein. On this basis, they also independently developed a kit that specifically detects heat shock protein 90α. Patients only need to take a drop of blood, which can be used for cancer condition monitoring and treatment effect evaluation.

In 2013, the Luo Yongzhang team teamed up with eight hospitals and collected 2,036 incoming samples. It completed the world's first clinical trial of using heat shock protein 90α as a lung cancer marker. It is the first time in the world that heat shock protein 90α is a new tumor marker. At present, China's independent research and development of Hsp90α quantitative detection kit has passed clinical trials, and has obtained the third and the highest category of medical device certificate. It has passed the EU certification and has been allowed to enter the Chinese and EU markets.

The State Food and Drug Administration quickly approved its use for the monitoring and evaluation of the efficacy of lung cancer patients. This is the first product in the world that has been found in the world for 24 years and Hsp90α has been used clinically.

After lung cancer, Luo Yongzhang's team completed a clinical study on liver cancer in 2016 and demonstrated for the first time in the world that heat shock protein 90α can be used for the detection of liver cancer patients and has now been approved by the State Food and Drug Administration for clinical use. In addition to the monitoring of liver and lung cancer, thanks to the heat shock protein 90α detection technology, when some cancers metastasize to the liver and lungs, doctors can obtain timely information to make the best treatment.

LED Emergency Twin Spot Light

Our LED Emergency Twin Spot Lights are a cost effective replacement for old fashioned halogen emergency twin spot fittings. Due to the low power consumption of the LED lamps, only one battery is required, reducing option during charging. The super bright adjustable heads make this twin spot ideal for commercial and industrial applications. with a self test feature every 90 days to ensure correct operation. The Led Emergency Lights design makes it quick and simple to install.

Twin Spot Emergency Light,Emergency Twin Spot,Led Twin Spot Emergency Lights,Led Emergency Twin Spot Light

Foshan Nai An Lighting Electric Co.,ltd , https://www.articalight.com